I got a chuckle out of your comment. I'd look pretty good in a tophat I guess.
Let me clarify something, my comments in post #163 are really more medium to longer term issues. I don't think they are affecting the short term. As far as this past week, a few things are happening. First, the stock is already highly valued at a 40+ P/E. Second, the market is waiting for confirmation of Lilly's earnings. They should release them within a week if they stick to past practice. In any case, it's not really an issue since they've already said they "are comfortable" with the Street's expectations. This has taken some of the upside surprise potential out of the stock in the short term.
Second, folks are waiting to see what happens as they start stocking Evista, as well as the continued performance of Zyprexa and Gemzar (and don't forget Prozac). Evista will get a quick start as they sell to stock initial inventories. The real key will be the "script" information, i.e. are the doc's writing a lot of prescriptions for Evista. This is key, so pay attention to any information you can find on what is happening with 'scripts being written for Evista.
Let me repeat, FOR 1998, Lilly is a buy at $65. It traded in the $64's twice over the past week or so. Did you get any? If Evista takes off like projected, Lilly could see $90 per share towards the end of 1998, but it will be with a whopper P/E attached to it, so no room for error.